ImmunityBio (IBRX) Stock Price, News & Analysis

Company Overview

ImmunityBio, Inc. is a biotechnology company focused on developing and commercializing immunotherapies and other treatments designed to activate the immune system against cancer and infectious diseases. The company’s platform combines biologics, cell therapies, vaccines and other approaches intended to generate durable immune responses.

Its lead product, ANKTIVA (nogapendekin alfa inbakicept-pmln), is an interleukin-15 receptor agonist designed to stimulate natural killer cells and T cells. In 2024, the U.S. Food and Drug Administration approved ANKTIVA in combination with Bacillus Calmette-Guérin for certain adults with BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ, with or without papillary tumors. ImmunityBio is also evaluating ANKTIVA and other investigational therapies in additional cancer settings.

ImmunityBio’s development programs have included cancer vaccines, engineered cell therapies and combination regimens intended to address solid tumors and other serious diseases. The company conducts clinical development and commercial activities primarily in the United States, while its therapies have been studied through international research programs. Patrick Soon-Shiong, M.D., is the company’s founder and executive chairman and has served as its chief executive officer.

Key Stats

• Today's Range: $7.80 to $8.35
• 50-Day Range: $6.83 to $8.91
• 52-Week Range: $1.95 to $12.43
• Volume: 12.44 million shs
• Average Volume: 7.45 million shs
• Market Capitalization: $8.38 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $14.20
• Consensus Rating: Moderate Buy

ImmunityBio Stock Analysis - MarketRank™

ImmunityBio scored higher than 43% of companies evaluated by MarketBeat, and ranked 632nd out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

ImmunityBio has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

ImmunityBio has a consensus price target of $14.20, representing about 79.5% upside from its current price of $7.91.

Amount of Analyst Coverage

ImmunityBio has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ImmunityBio are expected to grow in the coming year, from ($0.44) to ($0.14) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ImmunityBio is -8.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ImmunityBio is -8.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

34.97% of the float of ImmunityBio has been sold short.

Short Interest Ratio / Days to Cover

ImmunityBio has a short interest ratio ("days to cover") of 14.77, which indicates bearish sentiment.

Change versus previous month

Short interest in ImmunityBio has recently decreased by 1.46%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ImmunityBio does not currently pay a dividend.

Dividend Growth

ImmunityBio does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.55

News Sentiment

ImmunityBio has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for ImmunityBio this week, compared to 9 articles on an average week.

Search Interest

Only 13 people have searched for IBRX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

21 people have added ImmunityBio to their MarketBeat watchlist in the last 30 days. This is an increase of 110% compared to the previous 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, ImmunityBio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,753,442.00 in company stock.

Percentage Held by Insiders

66.10% of the stock of ImmunityBio is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

8.58% of the stock of ImmunityBio is held by institutions.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 9/12/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IBRX
• CIK: 1326110
• Web: immunitybio.com
• Phone: (844) 696-5235
• Fax: N/A
• Employees: 691
• Year Founded: 2014

Price Target and Rating

• Average Price Target for ImmunityBio: $14.20
• High Price Target: $23.00
• Low Price Target: $9.00
• Potential Upside/Downside: +79.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.97)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$351.40 million
• Net Margins: -598.55%
• Pretax Margin: -598.69%
• Return on Equity: N/A
• Return on Assets: -51.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.72
• Quick Ratio: 5.70

Sales & Book Value

• Annual Sales: $113.29 million
• Price / Sales: 74.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.51) per share
• Price / Book: -15.51

Miscellaneous

• Outstanding Shares: 1,059,840,000
• Free Float: 359,284,000
• Market Cap: $8.38 billion
• Optionable: Optionable
• Beta: 0.04